These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38932304)

  • 1. Cost-Effectiveness of Adjuvanted Quadrivalent Influenza Vaccine for Adults over 65 in France.
    Paccalin M; Gavazzi G; Berkovitch Q; Leleu H; Moreau R; Ciglia E; Burlet N; Mould-Quevedo JF
    Vaccines (Basel); 2024 May; 12(6):. PubMed ID: 38932304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Vaccination of Older Adults with an MF59
    Jacob J; Biering-Sørensen T; Holger Ehlers L; Edwards CH; Mohn KG; Nilsson A; Hjelmgren J; Ma W; Sharma Y; Ciglia E; Mould-Quevedo J
    Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany.
    Kohli MA; Maschio M; Cartier S; Mould-Quevedo J; Fricke FU
    Vaccines (Basel); 2022 Aug; 10(9):. PubMed ID: 36146464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine in the elderly Belgian population.
    Marbaix S; Dauby N; Mould-Quevedo J
    Expert Rev Vaccines; 2023; 22(1):608-619. PubMed ID: 37368472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population.
    Rumi F; Basile M; Cicchetti A; Alvarez FP; Azzi MV; Muzii B
    Front Public Health; 2023; 11():1200116. PubMed ID: 38026422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain.
    Ruiz-Aragón J; Márquez-Peláez S; Gani R; Alvarez P; Guerrero-Luduena R
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population.
    Fochesato A; Sottile S; Pugliese A; Márquez-Peláez S; Toro-Diaz H; Gani R; Alvarez P; Ruiz-Aragón J
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom.
    Kohli MA; Maschio M; Mould-Quevedo JF; Drummond M; Weinstein MC
    Hum Vaccin Immunother; 2021 Nov; 17(11):4603-4610. PubMed ID: 34550848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine for older adults in South Korea.
    Song Y; Shim E
    Hum Vaccin Immunother; 2024 Dec; 20(1):2348124. PubMed ID: 38714332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of the Use of Adjuvanted Quadrivalent Seasonal Influenza Vaccine in Older Adults in Ireland.
    Nguyen VH; Ashraf M; Mould-Quevedo JF
    Vaccines (Basel); 2023 May; 11(5):. PubMed ID: 37243037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate.
    Nham E; Seong H; Hyun H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Kim E; Choi L; Lee JM; Song JY
    Hum Vaccin Immunother; 2023 Dec; 19(3):2266233. PubMed ID: 37964587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies.
    Vesikari T; Ramsey K; Pitisuttithum P; Capeding R; Heijnen E; Sawlwin D; Oberyé J; Zhang B; Smolenov I
    Vaccine; 2020 Dec; 38(51):8224-8231. PubMed ID: 33139136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine.
    Redondo E; Drago G; López-Belmonte JL; Guillén JM; Bricout H; Alvarez FP; Callejo D; Gil de Miguel Á
    Vaccine; 2021 Aug; 39(36):5138-5145. PubMed ID: 34344553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
    Mullikin M; Tan L; Jansen JP; Van Ranst M; Farkas N; Petri E
    Infect Dis Ther; 2015 Dec; 4(4):459-87. PubMed ID: 26350238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparative Analysis of Influenza-Associated Disease Burden with Different Influenza Vaccination Strategies for the Elderly Population in South Korea.
    Choi MJ; Yun JW; Song JY; Ko K; Mould JF; Cheong HJ
    Vaccines (Basel); 2022 Aug; 10(9):. PubMed ID: 36146465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US.
    Pelton SI; Mould-Quevedo JF; Nguyen VH
    Expert Rev Vaccines; 2024; 23(1):82-87. PubMed ID: 38093415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
    Yan H; Yang J; Chen ZY; Gong H; Zhong GJ; Yu HJ
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2405-2412. PubMed ID: 34404135
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
    Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
    BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.
    Bianculli PM; Bellier L; Mangado IO; Pérez CG; Mieres G; Lazarov L; Petitjean A; Dibarboure H; Lopez JG
    Hum Vaccin Immunother; 2022 Nov; 18(5):2050653. PubMed ID: 35344679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain.
    Ruiz-Aragón J; Márquez-Peláez S
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.